Reappraising first-line treatment in glaucoma management.
Despite treatment, glaucoma patients may still suffer vision loss because of inadequate control of intraocular pressure or late presentation. This article reviews the latest evidence supporting a reappraisal of first-line treatment in the management of glaucoma, including a review of latanoprost, recently approved for first-line treatment of glaucoma and ocular hypertension.
D000577:Amides; D000959:Antihypertensive Agents / Q000627:therapeutic use; D000069580:Bimatoprost; D000068438:Brimonidine Tartrate; D003008:Cloprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D000077338:Latanoprost; D008055:Lipids / Q000627:therapeutic use; D011453:Prostaglandins / Q000627:therapeutic use; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use; D011810:Quinoxalines / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D000069557:Travoprost
D000577:Amides; D000959:Antihypertensive Agents; D008055:Lipids; D011453:Prostaglandins; D011461:Prostaglandins F, Synthetic; D011810:Quinoxalines; D013449:Sulfonamides; D013876:Thiophenes; D003008:Cloprostenol; D000068438:Brimonidine Tartrate; C072630:isopropyl unoprostone; D000077338:Latanoprost; C062765:dorzolamide; D015237:Dinoprost; D000069580:Bimatoprost; D000069557:Travoprost